Prominent Italian ALS expert Adriano Chiò joins TikoMed’s Scientific Advisory Board (SAB)
Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital as the fourth member of its newly formed Scientific Advisory Board.
Adriano Chiò is a neurologist currently working in Torino, Italy. He is Professor of Neurology and Director of the 1st Neurology Unit at the University of Torino and the Città della Salute e della Scienza Hospital, Torino, Italy. Professor Chiò is also a member of the board and Treasurer of the European Network for the Cure of ALS (ENCALS). In addition, he leads the Italian ALS Genetic (ITALSGEN) Consortium and is director of the ALS Expert Center in Torino which aims for optimal diagnostic work-up, care and treatment for patients with ALS/FTD and other motor neuron diseases in Piedmont.
Adriano Chiò, whose main areas of research are epidemiology, cognition, neuroimaging, and genetics of ALS, is best known for his research on risk of ALS in soccer players and the phenotypic heterogeneity of ALS and has contributed to the discovering of several ALS genes, including C9ORF72, VCP, MATR3 and KIF5A. He was awarded the 2015 Sheila Essay Award, presented by the American Academy of Neurology and ALS Association (USA) and has published over 350 papers in peer-reviewed journals.
“We are delighted to welcome Dr. Chiò to join our SAB,” said Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed. “With his vast experience and expertise spanning from the phenotypic heterogeneity of ALS to familial ALS, his advice will be of great importance as we advance our clinical program for the drug candidate ILB for treatment of ALS.”
Professor Chiò commented: “Understanding the phenotypic heterogeneity and identifying the causative genetic mutations is key to developing new treatments for ALS, and I look forward to contributing the knowledge gained by my various research teams in this area and ALS in general to TikoMed’s SAB.”
The SAB, which will advise management as Phase 2 clinical development of ILB progresses, includes highly experienced clinicians as well as seasoned industrial scientific leaders in the field.
Contact
Adam Bruce, Founder, Chairman of the Board and CEO of Tikomed
Phone: +46-70-8238444
Email: adam.bruce@tikomed.com.
TikoMed AB
TikoMed is committed to improve human life by exploring and harnessing the medical potential of the body’s ability to self-repair and regenerate. With an adaptive, multi-modal mechanism of action, TikoMed's drug platform has the potential to rebalance the body’s inflammatory, immune and fibrotic responses to acute and chronic inflammation to enhance self-repair and regeneration.
TikoMed’s initial development programs include Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation.
TikoMed’s highly scalable proprietary technology aims to provide innovative medicines to as many patients as possible across the globe.
TikoMed is privately owned and based in Viken, Sweden. To learn more, visit www.tikomed.com
